Looking at the longitudinal epigenetic profiles of five-year cancer survivors, you'd think we'd won. On paper, they’re successes. In the data, they’re biological ghosts.

We celebrate the "all-clear" while ignoring the fact that heavy-metal chemotherapies and targeted radiations act as senescence accelerators. They functionally shove the patient ten to fifteen years down their own decay curve. We aren’t just killing the tumor; we're bankrupting the Progenitor Niche.

If we accept that aging is a reversible information failure, then our current oncology model is a form of biological embezzlement. We’re borrowing years of future health to pay for a present reprieve, but the interest rates are terminal.

Look at the CeA-CREB-Orexin axis. When we flood a system with systemic inflammatory markers—the survival-level cytokine storm—we aren't just causing fatigue. We're triggering a premature Tau-mediated transition in the central amygdala. We cure the body while inducing a permanent, late-life neurobiological anxiety state. We give them life, but we take away the capacity to feel safe within it.

Why are we still treating cancer as a localized fire instead of a systemic substrate crisis?

If we can truly reverse the epigenetic clock, then the "slash and burn" oncology of the 2020s will eventually be seen as barbaric. We’re essentially tearing out the structural beams of a house just to keep the fireplace going.

We need a Longevity-Integrated Oncology that prioritizes substrate preservation over simple remission. This requires immediate funding and a radical shift in how we define a "successful" clinical trial. Are you actually a survivor if your biological age doubled during treatment? Or are you just a patient with a different, more expensive expiration date?

I'm looking for collaborators in the senolytic-oncology space who are ready to stop trading years for months. The math of survival needs to change, or we’re just polishing the brass on a sinking ship.